PMID- 29629947
OWN - NLM
STAT- MEDLINE
DCOM- 20200505
LR  - 20200505
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 27
IP  - 6
DP  - 2019 Jul
TI  - Identification of "Double Hit" Lymphomas Using Updated WHO Criteria: Insights 
      From Routine MYC Immunohistochemistry in 272 Consecutive Cases of Aggressive 
      B-Cell Lymphomas.
PG  - 410-415
LID - 10.1097/PAI.0000000000000657 [doi]
AB  - Aggressive lymphomas with MYC and BCL2 and/or BCL6 translocations ("double hit" 
      lymphomas, DHL) represent a distinct diagnostic category in the updated World 
      Health Organization (WHO) classification. The diagnostic yield of MYC 
      immunohistochemistry (IHC) for the identification of DHL is currently uncertain. 
      MYC IHC was performed in 272 consecutive cases of aggressive B-cell lymphoma, and 
      results correlated with fluorescence in situ hybridization (FISH) for MYC 
      translocations. Among 156 patients with IHC and FISH data, MYC IHC identified MYC 
      translocations with 89% sensitivity, 38% specificity, 92% negative predictive 
      value, and 29% positive predictive value. Three of 15 (20%) of DHL were MYC IHC 
      negative. One case contained a MYC translocation detectable IGH/MYC fusion probes 
      but not MYC break-apart probes. A subset of DHL lack MYC protein expression, and 
      recognition of this subset of cases requires FISH testing. These results provide 
      an appropriate diagnostic algorithm for implementation of 2016 WHO diagnostic 
      criteria.
FAU - Sakr, Hany
AU  - Sakr H
AD  - Department of Laboratory Medicine, Robert J. Tomsich Pathology and Laboratory 
      Medicine Institute, Cleveland Clinic, Cleveland, OH.
FAU - Cook, James R
AU  - Cook JR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Algorithms
MH  - Biomarkers, Tumor/*metabolism
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, B-Cell/*diagnosis
MH  - Predictive Value of Tests
MH  - Proto-Oncogene Proteins c-bcl-2/genetics/metabolism
MH  - Proto-Oncogene Proteins c-bcl-6/genetics/metabolism
MH  - Proto-Oncogene Proteins c-myc/genetics/*metabolism
MH  - Sensitivity and Specificity
MH  - World Health Organization
EDAT- 2018/04/10 06:00
MHDA- 2020/05/06 06:00
CRDT- 2018/04/10 06:00
PHST- 2018/04/10 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2018/04/10 06:00 [entrez]
AID - 10.1097/PAI.0000000000000657 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2019 Jul;27(6):410-415. doi: 
      10.1097/PAI.0000000000000657.